Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma
Open Access
Abstract
BACKGROUND Elevated serum carcinoembryonic antigen (CEA) levels are sometimes attributable to the production of CEA by malignant cells, and in turn, the antigen itself can enhance the metastatic potential of malignant cells. The authors speculated that low serum CEA levels might be indicative of relatively low levels of malignant cells and a low probability of disease recurrence. This hypothesis led them to investigate whether low CEA levels in serum represented a useful prognostic factor for patients with pathologic Stage IA nonsmall cell lung carcinoma. METHODS Between 1993 and 2001, 724 patients underwent surgery for NSCLC at Toneyama National Hospital (Toyonaka, Japan). Of these patients, the 242 who were diagnosed with pathologic Stage IA disease were included in the current study. Smoking behavior, gender, age, tumor diameter, disease histology, and preoperative and postoperative serum CEA levels were chosen as study variables, with the cutoff level between subnormal and normal serum CEA levels set at 2.5 ng/mL and the cutoff level between normal and high serum CEA levels set at 5.0 ng/mL. Prognostic indicators were evaluated using a Cox hazard model. In addition, survival probabilities were calculated using the Kaplan–Meier method, and differences in survival were assessed by log‐lank analysis. RESULTS Subnormal postoperative serum CEA levels were found to be an independent prognostic indicator (hazard ratio, 2.3; 95% confidence interval, 1.1–4.7; P = 0.03 for comparison with patients who had normal CEA levels) on multivariate analysis. Furthermore, the 5‐year survival rate was 87% for patients with subnormal postoperative CEA levels (n = 146), compared with 75% for patients with normal postoperative CEA levels (n = 80) and 53% for patients with high postoperative CEA levels (n = 16) (P < 0.0001). CONCLUSIONS Among patients with pathologic Stage IA NSCLC, those who had an extremely favorable prognosis were distinguished by their subnormal postoperative serum CEA levels. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Discrepancy in serum carcinoembryonic antigen levels by measuring kits.The Annals of Thoracic Surgery, 2004
- Clinical value of p53, c‐erbB‐2, CEA and CA125 regarding relapse, metastasis and death in resectable non‐small cell lung cancerInternational Journal of Cancer, 2003
- Characteristics and prognosis of patients after resection of nonsmall cell lung carcinoma measuring 2 cm or less in greatest dimensionCancer, 2003
- Prognostic factors in clinical stage I non–small cell lung cancerThe Annals of Thoracic Surgery, 1999
- p53 Status Predicts the Efficacy of Postoperative Oral Administration of Tegafur for Completely Resected Non-small Cell Lung Cancer†Japanese Journal of Cancer Research, 1999
- Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Analysis of carcinoembryonic antigen (CEA) level in pulmonary adenocarcinoma-Changes in CEA levels and survival.The Journal of the Japanese Association for Chest Surgery, 1998
- CEA, CYFRA21-1 and SCC in non-small cell lung cancerLung Cancer, 1995
- Carcinoembryonic antigen in 228 patients with carcinoma of the lungCancer, 1975
- Carcinoembryonic antigen in 228 patients with carcinoma of the lungCancer, 1975